Dr. Clay Siegall is one of the most prominent biotechnologists based in the United States. For over two decades of professional as a biotechnologist working for various companies in the United States, Dr. Clay Siegall gained enough experience to set up his company towards finding the solution to numerous medical illness in and out of the United States. Dr. Clay Siegall has always had a passion towards assisting cancer patients in the country. This is because cancer is a leading cause of death in and out of the United States. While cancer has been there for the longest time possible, no one has come up with its cure in the industry. For this reason, Dr. Clay Siegall decided that he would work towards finding its cure even if it takes his lifetime. Dr. Clay Siegall’s mother also died as a result of cancer when he was still a teenager. This made him have a passion towards fighting the disease till the end of his life so that other cancer patients will not follow the same path his mother followed.
Dr. Clay Siegall is the Chief Executive Officer and Founder of the Seattle Genetics Company based in the United States. Dr. Clay Siegall worked in the biotechnology industry for 10 years before he decided to found the Seattle Genetics Company in 1998. During that time, he used to work at the Apex Industries that produces most of the medical solutions in the industry. Dr. Clay Siegall worked as the lead scientist for new medical inventions that were approved by the FDA under his care as a manager. When he announced that he was about to quit his job, Dr. Clay Siegall wanted to assimilate better business through a wide range of business solutions. However, his decision was stern.
Dr. Clay Siegall is a graduate of the University of Maryland with the highest honors in a Zoology degree. When he graduated he was determined to push further in the line of education, he pursued a master’s degree from the same university. After graduation, Dr. Clay Siegall also went on to graduate from the Washington State University with a post-doctorate degree in Biotechnology.
Several organizations have come up to deal with cancer, and one of these companies which have been in existence for an extended period now is Seattle Genetics. Recently the Chief Executive Officer of Seattle Genetics Clay Siegall was speaking about the company’s innovation and its advancement in cancer therapy. The fact that its prices have been tripling over five years, it clearly shows the growth of the enterprise.
Dr. Clay Siegall has been very passionate about cancer therapy and has been making continuous efforts to improve the lives of cancer patients. Clay Siegall began his career in biomedical studies. Currently, he is Chairman and the Chief Executive Officer of Settle Genetics, a position he has held since 2002. Clay Siegall is the co-founder of the medical organization which was established in 1998. Since its foundation, Clay has been working effortlessly to take the firm into greater levels and realize revolutionary therapies for cancer patients.
Dr. Clay Siegall earned his Ph.D. in Genetics from George Washington University, and since then he has made several accomplishments in the medical and research sector. Before co-founding Seattle, he has served in several organization including; Bristol-Myers Squibb Pharmaceutical Research Institute where he began his career. Clay is a very determined man, and his efforts led to him climbing the career ladder to the position of a Principal Scientist before becoming a member of National Cancer Institute. His vast experience in the institutions gave him an opportunity to establish Seattle Genetics.
Clay Siegall’s accomplishments have been a commitment to concentrate on relevant research and being industrious on the execution on the most significant research developments. His hard work has been led by the desire to assist cancer patients. Mr. Clay’s passion for helping cancer patients has helped him take the company to a high level regarding research advancement. Under his tenure, the pharmaceutical organization has been able to develop its first Antibody Drug Conjugates (ADCs) including ADCETRIS which was approved by FDA in 2011. Since its development, the drug has been expanding its international impact, and it is now available in more than 60 nations world over.